CA2960830C - Detection of misfolded proteins - Google Patents
Detection of misfolded proteins Download PDFInfo
- Publication number
- CA2960830C CA2960830C CA2960830A CA2960830A CA2960830C CA 2960830 C CA2960830 C CA 2960830C CA 2960830 A CA2960830 A CA 2960830A CA 2960830 A CA2960830 A CA 2960830A CA 2960830 C CA2960830 C CA 2960830C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- misfolded
- soluble
- incubation mixture
- incubation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049306P | 2014-09-11 | 2014-09-11 | |
| US62/049,306 | 2014-09-11 | ||
| PCT/US2015/049844 WO2016040907A1 (en) | 2014-09-11 | 2015-09-11 | Detection of misfolded proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2960830A1 CA2960830A1 (en) | 2016-03-17 |
| CA2960830C true CA2960830C (en) | 2023-09-05 |
Family
ID=55454515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2960830A Active CA2960830C (en) | 2014-09-11 | 2015-09-11 | Detection of misfolded proteins |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160077112A1 (enExample) |
| EP (2) | EP4292654A3 (enExample) |
| JP (2) | JP6980953B2 (enExample) |
| KR (1) | KR102448128B1 (enExample) |
| CN (1) | CN107208125A (enExample) |
| AU (1) | AU2015314783B2 (enExample) |
| BR (1) | BR112017004899A2 (enExample) |
| CA (1) | CA2960830C (enExample) |
| ES (1) | ES2953855T3 (enExample) |
| HR (1) | HRP20231232T1 (enExample) |
| IL (2) | IL251052B (enExample) |
| MX (1) | MX2017003269A (enExample) |
| PL (1) | PL3191599T3 (enExample) |
| SG (2) | SG11201701953RA (enExample) |
| WO (1) | WO2016040907A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| GB201611840D0 (en) * | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| TW201901153A (zh) * | 2017-05-16 | 2019-01-01 | 美商安培恩股份有限公司 | 折疊錯誤之tau蛋白的檢測及檢測折疊錯誤之tau蛋白的套組 |
| US11313867B2 (en) | 2017-10-02 | 2022-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| WO2019121952A1 (en) * | 2017-12-21 | 2019-06-27 | H. Lundbeck A/S | Assay, method and treatment of alpha-synucleinopathies |
| CN108088816A (zh) * | 2018-01-23 | 2018-05-29 | 深圳市国赛生物技术有限公司 | 小型特定蛋白分析仪 |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| WO2019222554A2 (en) * | 2018-05-16 | 2019-11-21 | Amprion, Inc. | Detection of brain injury or neurological disease using tau protein |
| CA3110200C (en) | 2018-09-21 | 2023-08-08 | Deepmind Technologies Limited | Iterative protein structure prediction using gradients of quality scores |
| JP7376040B2 (ja) * | 2019-09-03 | 2023-11-08 | 国立大学法人京都工芸繊維大学 | 神経変性疾患におけるバイオマーカー分子の検出方法 |
| CN115003824A (zh) * | 2019-09-04 | 2022-09-02 | 安培里翁公司 | 使用珠子检测α-突触核蛋白 |
| KR102277871B1 (ko) * | 2019-12-17 | 2021-07-15 | 원광대학교산학협력단 | 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트 |
| WO2021198098A1 (en) | 2020-04-03 | 2021-10-07 | Universität Zürich | Improved method of detecting biomarkers in a biological sample |
| WO2021236678A1 (en) * | 2020-05-18 | 2021-11-25 | Amprion, Inc. | Alpha-synuclein substrates and methods for making and using the same |
| CN118731363A (zh) * | 2020-11-21 | 2024-10-01 | 浙江数问生物技术有限公司 | 用于检测生物样本中的错误折叠蛋白质的装置和方法 |
| US20240192230A1 (en) * | 2021-04-15 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Digital Protein Misfolding Assays |
| CN114199875B (zh) * | 2022-02-18 | 2022-05-20 | 之江实验室 | 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA007391B1 (ru) | 2000-07-07 | 2006-10-27 | Апплайд Резеч Системз Арс Холдинг Н.В. | Способ диагностики или выявления конформационного заболевания или его маркера и набор для использования в способе |
| EP1366368A2 (en) | 2001-01-03 | 2003-12-03 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| EP1820806A1 (en) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinity regions |
| EP1853915B1 (en) * | 2005-02-15 | 2011-10-12 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
| BRPI0712034A2 (pt) * | 2006-05-19 | 2012-01-10 | Alnylam Pharmaceuticals Inc | modulação de rnai de aha e usos terapêuticos do mesmo |
| WO2008030973A2 (en) * | 2006-09-06 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of protein folding disorders |
| JP2010043865A (ja) * | 2006-12-12 | 2010-02-25 | Olympus Corp | 異常型プリオンの検出方法 |
| JP2013511734A (ja) * | 2009-11-24 | 2013-04-04 | プロビオドルグ エージー | アルツハイマー病又は軽度認知障害の診断のための新規診断方法 |
| US9133343B2 (en) * | 2009-11-30 | 2015-09-15 | Enzo Biochem, Inc. | Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications |
| AU2012207454B2 (en) * | 2011-01-18 | 2016-11-17 | Prionics Ag | Methods for amplification and detection of prions |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| WO2016040903A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
-
2015
- 2015-09-11 EP EP23189057.5A patent/EP4292654A3/en active Pending
- 2015-09-11 BR BR112017004899A patent/BR112017004899A2/pt not_active Application Discontinuation
- 2015-09-11 SG SG11201701953RA patent/SG11201701953RA/en unknown
- 2015-09-11 JP JP2017533721A patent/JP6980953B2/ja active Active
- 2015-09-11 PL PL15839278.7T patent/PL3191599T3/pl unknown
- 2015-09-11 AU AU2015314783A patent/AU2015314783B2/en active Active
- 2015-09-11 KR KR1020177009707A patent/KR102448128B1/ko active Active
- 2015-09-11 CN CN201580058606.3A patent/CN107208125A/zh active Pending
- 2015-09-11 US US14/852,478 patent/US20160077112A1/en not_active Abandoned
- 2015-09-11 CA CA2960830A patent/CA2960830C/en active Active
- 2015-09-11 MX MX2017003269A patent/MX2017003269A/es unknown
- 2015-09-11 HR HRP20231232TT patent/HRP20231232T1/hr unknown
- 2015-09-11 SG SG10202008464UA patent/SG10202008464UA/en unknown
- 2015-09-11 ES ES15839278T patent/ES2953855T3/es active Active
- 2015-09-11 WO PCT/US2015/049844 patent/WO2016040907A1/en not_active Ceased
- 2015-09-11 EP EP15839278.7A patent/EP3191599B1/en active Active
-
2017
- 2017-03-09 IL IL251052A patent/IL251052B/en unknown
-
2021
- 2021-05-12 JP JP2021081274A patent/JP7104943B2/ja active Active
-
2022
- 2022-03-30 IL IL291809A patent/IL291809B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2953855T3 (es) | 2023-11-16 |
| JP6980953B2 (ja) | 2021-12-15 |
| CA2960830A1 (en) | 2016-03-17 |
| AU2015314783A1 (en) | 2017-04-27 |
| BR112017004899A2 (pt) | 2017-12-12 |
| KR20170103741A (ko) | 2017-09-13 |
| JP7104943B2 (ja) | 2022-07-22 |
| IL251052A0 (en) | 2017-04-30 |
| IL291809B2 (en) | 2023-06-01 |
| IL251052B (en) | 2022-05-01 |
| EP3191599A1 (en) | 2017-07-19 |
| JP2017530373A (ja) | 2017-10-12 |
| IL291809A (en) | 2022-06-01 |
| AU2015314783B2 (en) | 2021-10-21 |
| HRP20231232T1 (hr) | 2024-01-19 |
| EP4292654A2 (en) | 2023-12-20 |
| JP2022000629A (ja) | 2022-01-04 |
| US20160077112A1 (en) | 2016-03-17 |
| EP4292654A3 (en) | 2024-01-03 |
| CN107208125A (zh) | 2017-09-26 |
| KR102448128B1 (ko) | 2022-09-27 |
| EP3191599B1 (en) | 2023-08-02 |
| EP3191599C0 (en) | 2023-08-02 |
| SG11201701953RA (en) | 2017-04-27 |
| PL3191599T3 (pl) | 2023-12-27 |
| MX2017003269A (es) | 2017-12-04 |
| SG10202008464UA (en) | 2020-10-29 |
| EP3191599A4 (en) | 2018-03-14 |
| WO2016040907A1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2960830C (en) | Detection of misfolded proteins | |
| US20240219406A1 (en) | Detection of misfolded alpha synuclein protein | |
| US9910049B2 (en) | Detection of misfolded amyloid beta protein | |
| US20220137073A1 (en) | Detection of misfolded tau protein | |
| US20210102961A1 (en) | Detection of misfolded proteins | |
| HK40105178A (en) | Detection of misfolded proteins | |
| US20190137515A1 (en) | Methods for estimating misfolded protein concentration in fluids and tissue by quantitative pmca | |
| US20190353669A1 (en) | Detection of Brain Injury or Neurological Disease using Tau Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |
|
| EEER | Examination request |
Effective date: 20180911 |